Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Transcatheter Device By Medtronic PLC (MDT) Gets FDA Nod

The Melody Transcatheter Pulmonary Valve that has been developed by Medtronic PLC. Ordinary Shares (NYSE:MDT) has been approved by the U.S. Food and Drug Administration. The device is implanted in patients in cases where surgical pulmonary heart valves are not working. This transcatheter pulmonary valve is the first of its kind to be approved in the United States.

“Melody TPV is uniquely designed for use in the pulmonic position and is thus well suited for implantation in failed surgical pulmonary heart valves. This approval further demonstrates our commitment to improving treatment options for congenital heart disease…,” Rhonda Robb, a general manager and vice president at a Medtronic subsidiary said.

Most Advanced Countries in Medicine

everything possible/

Open-Heart Surgery

In cases where a surgical valve has degenerated over the course of time, a replacement is normally required and this usually involves open-heart surgery. But with the Melody Transcatheter Pulmonary Valve, patients now have an option that is minimally invasive. In the course of the procedure to place the Melody TPV inside the surgical pulmonary valve that is failing, a delivery catheter which has been designed specifically for this purpose is utilized.

As the pioneering transcatheter heart valve in the world, this device has been implanted in patients numbering more than 10,000 across the globe. This device first got the CE Mark more than a decade ago, during which time numerous trials have proven the efficacy of the device in delaying open heart surgery with a view to replacing the broken pulmonary heart valve. It was first launched in the United States in 2010 after getting the approval of the Food and Drug Administration.

Global Reach

With the transcatheter valve market expected to be worth $8.62 billion globally, Medtronic PLC. Ordinary Shares (NYSE:MDT) is well placed to take advantage. Besides the Melody TPV, Medtronic has a wide range of devices and technologies that are used in treating cardiac arrhythmias and cardiovascular diseases. The Dublin, Ireland-based medical technology firm is among the largest in the world in its space. It has a presence in over 160 countries and employs over 88,000 people across the globe.

In Thursday’s trading session, shares of Medtronic PLC. Ordinary Shares (NYSE:MDT) fell by 1.76% to close the day at $81.83 a share.

Follow Medtronic Plc (NYSE:MDT)
Trade (NYSE:MDT) Now!

Note: This article is written by Adam Russell and was originally published at Market Exclusive.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.